EORTC selected abstracts at ASCO 2021

ASCO Annual Meeting will take place virtually from 4 to 8 June 2021.

7 EORTC abstracts were accepted for the conference.


Oral sessions

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

Date: Sunday 6 June, 14:00-17:00 CEST

Abstract number: 9500

Authors: Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandala, Georgina V. Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Stephens, Shahneen Kaur Sandhu, Ragini Reiney Kudchadkar, Pablo L. Ortiz-Romero, Inge Marie Svane, Alexander Christopher Jonathan Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert


Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial

Date: Sunday 6 June, 14:00-17:00 CEST

Abstract number: 500

Authors: Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van ‘t Veer, Annuska Glas, A. Witteveen, Fatima Cardoso, Martine J. Piccart-Gebhart, Coralie Poncet, Emiel J. Rutgers


EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

Date: Monday 7 June, 14:00-17:00 CEST

Abstract number: 2400

Authors: Patrick Roth, Thierry Gorlia, Jaap C. Reijneveld, Filip Yves Francine Leon De Vos, Ahmed ldbaih, Jean­Sebastien Frenel, Emilie Le Rhun, Jose Manuel Sepulveda Sanchez, James R. Perry, Laura Masucci, Pierre Freres, Hal W. Hirte, Clemens Seidel, Anna Maria Elisabeth Walenkamp, Frederic Dhermain, Martin J. Van Den Bent, Christopher J. O’Callaghan, Maureen Vanlancker, Warren P. Mason, Michael Weller

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII Trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis

Date: Tuesday 8 June, 14:00-17:00 CEST

Abstract number: 5002

Authors: Silke Gillessen, Ananya Choudhury, Alejo Rodriguez-Vida, Franco Nole, Enrique Gallardo Diaz, Thierry Andre Roumeguere, Gedske Daugaard, Yohann Lariat, Fred Saad, Raymond S. McDermott, Anouk Neven, Beatrice Fournier, Bertrand F. Tombal


Poster sessions

Critical impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial

Date: Friday 4 June

Abstract number: 11566

Authors: Rick L.M. Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, Enrico Clemente!, Raquel Bar Deroma, Cecile Le Pechoux, Saskia Litiere, Sandrine Marreaud, Najlaa Alyamani, Nicolaus Andratschke, Claudia Sangalli, Peter W. M. Chung, Aisha Miah, Coen Hurkmans, Alessandro Gronchi, Judith V.M.G. Bovee, Hans Gelderblom, Bernd Kasper, Damien Weber, Sylvie Bonvalot


Updated results of EORTC Phase II trial of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma

Date: Friday 4 June

Abstract number: 11518

Authors: Roberta Sanfilippo, Richard L Hayward, Jammbe Musoro, Charlotte Benson, Michael Gordon Leahy, Antonella Brunello,Jean-Yves Blay, Neeltje Steeghs, Ingrid Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper


Online publication

Coverage of symptomatic toxicities from the common terminology criteria for adverse events (CTCAE) framework within the European Organization for Research and Treatment of Cancer (EORTC) item library.

Abstract number: e24117

Authors: Claire Piccinin, Andrew Bottomley, Galina Velikova, Mogens Groenvold, Dagmara Kulis, Jane M. Blazeby, Alexandra Gilbert


More information on the 2021 ASCO Annual Conference website.

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023